EGFR-TKI
Postoperative survival of EGFR TKI targeted therapy in non small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
... first-line EGFR-TKIs that are effective at treating ...the EGFR exon 19 deletion group and EGFR L858R group, ...after EGFR-TKI treatment than gefitinib and erlotinib in both exon 19 ...
8
FAM83A confers EGFR TKI resistance in breast cancer cells and in mice
... of EGFR is observed in many cancers, including 30% of breast cancers ...the EGFR antibody cetuximab and EGFR-TKI’s lapatinib, erlotinib, or gefi- tinib, but amplification and overexpression assays ...
11
Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells
... by EGFR-TKI (Figure 2 and Supplemental Figure 1), it is possible that erlotinib treatment has an influence on the expression of SEMA7A in SEMA7A WT ...during EGFR-TKI treatment and found that ...
18
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
... that EGFR mutation in general, and secondary T790M mutation can be detected in the plasma of resistant patients with high prevalence [8–21], and even be detected earlier than the disease pro- gression [11, 14, 15, ...
18
The emergence of T790M mutation in EGFR -mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
... of EGFR-TKI ...under EGFR-TKI treatment at the time of rebiopsy and their median interval from the progression to initial EGFR-TKI treatment was 325 days (range 74–818 ...median ...
11
Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
... to EGFR mutation, the efficacy of EGFR- TKI, and the predictive value of ...with EGFR-TKI harboring EGFR ...HDL-C. EGFR mutation rate of HDL-C high-level group was ...
8
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
... that EGFR mutations can drive alterations in metabolism [16, 36, 37], indicating that metabolic repro- gramming plays a vital role in the emergence of EGFR-TKI ...resistant EGFR mutations ...
20
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
... generation EGFR-TKI and crizotinib was tested in two patients with newly acquired MET amplification after osimertinib ...harboring EGFR L858R mutation had emergent MET amplification after disease ...
11
A Significance of MMP-1 in EGFR-TKI Resistant Lung Adenocarcinoma: A Potential of Therapeutic Target
... that EGFR pathway, especially mTOR related EGFR pathway was significantly associated with the induction of MMP-1 expression in PC9 cells and PC9/ER ...that EGFR pathway is important for the induction ...
17
EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR TKI
... with EGFR-tyrosine kinase in- hibitors ...the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with ...the EGFR gene were evaluated in 71 NSCLC ...
8
Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI ) rechallenge in small cell transformation after EGFR-TKI failure: a case report
... falls short of expectations. The present study highlights the advantages of combination of rechallenge with chemotherapy as well as first-line TKIs in cases of tumor heterogeneity of acquired resistance following ...
5
Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
... cases). EGFR mutation status analyzed by ARMS revealed exon 19 E746_A750 deletions in 118 patients, exon 21 L858 mutations in 158 patients, and double mutations in four ...and EGFR-TKI before the ...
12
EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
... comparing EGFR-TKI-based and non-EGFR-TKI- based adjuvant therapies in postoperative NSCLC patients who harboring sensitive EGFR ...comparing EGFR-TKI-based and ...
8
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
... ried EGFR mutations with afatinib, a second-generation, irreversible EGFR-TKI ...with EGFR 19 del who received afatinib treat- ment had a significantly longer OS compared with those treated ...
10
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
... Third-generation EGFR-TKIs, such as osimertinib, are active against both EGFR sensitizing mutant and T790M resistant tumors ...of EGFR gene was found as sufficient to promote resist- ance to ...
12
A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer
... to EGFR-TKI [26] and chemotherapeutic drugs, such as cisplatin, doxorubicin or sulfasalazine ...[27–29]. EGFR activation induced transactivation of AXL, which leads to diversification of downstream ...
13
Original Article Pemetrexed combined with cisplatin for patients with EGFR-TKI resistant advanced lung cancer
... Inclusion criteria: Patients pathologically diag- nosed with advanced lung cancer; Patients pathologically diagnosed as stage III or IV; Patients that met the criteria [8] for acquired EGFR-TKI resistance. ...
8
Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient
... of EGFR-TKI therapy ...to EGFR-TKI therapy ...in EGFR-mutation patients in autopsy and genotype ...of EGFR mutation, it was detected in only 5 (4%) ...harbored EGFR ...
5
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
... of EGFR mutation, BIM-del, response to TKIs, ECOG and brain metastases) to identify factors associated with PFS and ...of EGFR mutation [common mutations (L858R and exon 19 deletion) ...mutations], ...
10
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
... prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaïve patients with EGFR-mutant lung ...with EGFR-mutant lung adenocarcinoma receiving PP as ...
7